-
公开(公告)号：US20230162833A1
公开(公告)日：2023-05-25
申请号：US18151582
申请日：2023-01-09
Applicant: INSULET CORPORATION
Inventor： David NAZZARO , Steven CARDINALI , Nicholas CONTE , Daniel ALLIS , Jason O'CONNOR , Joon Bok LEE , Ashutosh ZADE , Timothy HENNING , Thomas METZMAKER , Ian MCLAUGHLIN
Abstract: Disclosed are examples of a device, a system, methods and computer-readable medium products operable to implement functionality to determine and respond to a purpose of a meal. An algorithm or application may receive data that may include data related to a meal purpose from data sources and determine whether any of the data received from the plurality of data sources was received from a direct data source or an indirect data source. The data may be evaluated to determine a purpose of the meal. Based on the results of the evaluation, instructions may be generated to provide an appropriate response based on the determined purpose of the meal. The generated instructions to provide the appropriate response based on the determined purpose of the meal may be output.
-
公开(公告)号：US20230060939A1
公开(公告)日：2023-03-02
申请号：US17821653
申请日：2022-08-23
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Ashutosh ZADE , Yibin ZHENG , Jason O'CONNOR
Abstract: The insulin to carbohydrate ratio (ICR) and the correction factor for a user of a medicament delivery device may be automatically adjusted. The automatic adjustments may tailor the values to the user's actual insulin needs. Various factors may be examined to determine how to adjust the ICR and the correction factor. The identified factors are weighed with the processor to decide whether to increase or decrease the insulin to carbohydrate ratio or the correction factor. The insulin to carbohydrate ratio or the correction factor for the user are adjusted based on the weights of the identified factors. In addition or in the alternative, automatic adjustments of user-requested insulin boluses may be made to requested dosages and timing of deliveries of the insulin boluses. In some instances, the exemplary embodiments may deliver a percentage of the insulin bolus dosage initially and deliver the remaining percentage after a delay to reduce the risk of hypoglycemia for the user.
-
33.发明申请公开(公告)号：US20220241504A1
公开(公告)日：2022-08-04
申请号：US17582349
申请日：2022-01-24
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Jason O'CONNOR , Yibin ZHENG , Ashutosh ZADE
Abstract: Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
-
公开(公告)号：US20220240847A1
公开(公告)日：2022-08-04
申请号：US17582374
申请日：2022-01-24
Applicant: Insulet Corporation
Inventor： Joon Bok LEE , Jason O'CONNOR , Yibin ZHENG , Ashutosh ZADE
Abstract: Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.
-
公开(公告)号：US20210236726A1
公开(公告)日：2021-08-05
申请号：US16780278
申请日：2020-02-03
Applicant: Insulet Corporation
Inventor： Steven CARDINALI , Ashutosh ZADE , Joon Bok LEE , Jason O'CONNOR , Yibin ZHENG
IPC: A61M5/172
Abstract: Exemplary embodiments may provide an improved approach to automated insulin delivery by more accurately estimating the total daily insulin (TDI) of a user. As a result, less insulin is wasted by the delivery system, and the estimate of TDI more closely matches a user's actual daily insulin needs. Hence, the user need not refill the insulin reservoir excessively or need not fret unnecessarily about running out of insulin prematurely. The estimate relies on the history of actual automated insulin deliveries and thus reflects the actual insulin delivered to the user more accurately than conventional approaches.
-
Patent Agency Ranking
36.发明申请公开(公告)号：US20250144295A1
公开(公告)日：2025-05-08
申请号：US19017941
申请日：2025-01-13
Applicant: INSULET CORPORATION
Inventor： Yibin ZHENG , Joon Bok LEE , Ashutosh ZADE , Jason O'CONNOR
Abstract: Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.
-
公开(公告)号：US20250082842A1
公开(公告)日：2025-03-13
申请号：US18883710
申请日：2024-09-12
Applicant: INSULET CORPORATION
Inventor： John BUSSIERE , Joon Bok LEE , Yibin ZHENG , Ashutosh ZADE , Jason O’CONNOR
Abstract: In an aspect, an adhesive patch is presented. The adhesive patch has a top surface configured to adhere to a wearable medical device. The adhesive patch has a bottom surface opposite the top surface, wherein the bottom surface includes an adhesive layer configured to adhere to a user's skin. The adhesive patch has a first perforation extending through the top and bottom surfaces, the first perforation configured to receive a piercing element from the wearable medical device.
-
38.发明公开公开(公告)号：US20240197990A1
公开(公告)日：2024-06-20
申请号：US18530449
申请日：2023-12-06
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , James CAUSEY , Ashutosh ZADE , Jason O’CONNOR
IPC: A61M5/172
CPC classification number: A61M5/1723 , A61M2205/70 , A61M2230/201
Abstract: Compensation may be provided for the varying accuracy levels of a sensor over time. As a result of the compensation, the medicament delivery device may perform better. The sensor may provide input to a medicament delivery device, and the input may be used to determine a dose of medicament to be delivered to a user by the medicament delivery device. A degree of inaccuracy of sensor values may be determined based on when in the lifetime a sensor value is generated. Glucose level values read by a glucose monitor, such as a CGM, may be directly modified before being used by an automated insulin delivery (AID) control of an insulin delivery device. The compensation for the inaccuracy of the glucose level values from the glucose monitor instead may be achieved by modifying a weight coefficient of a glucose cost component of a cost function in one example.
-
公开(公告)号：US20230381414A1
公开(公告)日：2023-11-30
申请号：US18323538
申请日：2023-05-25
Applicant: INSULET CORPORATION
Inventor： Joon Bok LEE , Jason O'CONNOR , Yibin ZHENG , Ashutosh ZADE
CPC classification number: A61M5/1723 , G16H20/17 , G16H10/60
Abstract: Disclosed are techniques, devices and systems that obtain a glucose measurement history and a liquid drug delivery history. An expected drug delivery amount may be calculated based on the obtained glucose measurement history and the obtained liquid drug delivery history. A processor may calculate a plurality of respective drug delivery amounts implemented using different advisory mode algorithms. A respective advisory drug delivery amount of the plurality of respective advisory drug delivery amounts may be selected by the processor. A recommendation may be generated based on the selected respective advisory drug delivery amount.
-
公开(公告)号：US20230377706A1
公开(公告)日：2023-11-23
申请号：US18199641
申请日：2023-05-19
Applicant: INSULET CORPORATION
Inventor： Yibin ZHENG , Joon Bok LEE , Ashutosh ZADE , William WHITELEY , Jason O’CONNOR
CPC classification number: G16H20/10 , A61B5/14532 , A61B5/4839 , G16H40/63
Abstract: The exemplary embodiments may dynamically adjust an Insulin on Board (JOB) profile for a user of a medicament delivery system to customize the IOB profile to the user based on recent glucose level history and insulin deliveries rather than use the conventional static IOB profiles that are based on population averages. The exemplary embodiments may calculate a Duration of Insulin Action (DIA) for a user from the customized insulin decay curves. The exemplary embodiments may generate and send notifications to the user to help reduce the DIA of the user and/or to keep the DIA of the user from rising. The exemplary embodiments may aim to not overly constrain insulin delivery due to the contribution of insulin boluses to JOB.
-
-
-
-
-
-
-
-
-
Search Results
48
records
(took 0.018 seconds)
